📰 Angioedema Workshop News
Angioedema Workshop News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Angioedema Workshop. Real-time updates on events, politics, business and more.
August 8, 2023
-- STAR-0215 Granted Fast Track Designation by the U.S. FDA ---- New Results from Healthy Subjects Informing STAR-0215 Administration Plan Expected in Q4 2023 ---- ALPHA-STAR on Track with Initial Proof-of-Concept Results in Patients Anticipated Mid-2024 --BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:A...
August 7, 2023
Enrollment completed in Phase 2 CHAPTER-1 prophylactic study; top-line data anticipated by YE2023Clinical hold lifted on deucrictibant for the on-demand treatment of HAE; initiation of global Phase 3...
July 7, 2023
– Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Target Enrollment; Data Readout Expected in Q4 – – Company Funded Into 2025 With NDA Planned for H1 2024 –
May 12, 2023
-- Administration of STAR-0215 to HAE Patients is Underway in the ALPHA-STAR Phase 1b/2 Trial ---- ALPHA-STAR on Track for Initial Proof-of-Concept Results Anticipated Mid-2024 ---- Mechanistic Modeling Data Supports STAR-0215 Administration Once Every Three or Six Months for Robust Suppression of HAE Attacks --BOST...
May 11, 2023
-- Administration of STAR-0215 to HAE Patients is Underway in the ALPHA-STAR Phase 1b/2 Trial -- -- ALPHA-STAR on Track for Initial Proof-of-Concept Results Anticipated Mid-2024 -- -- Mechanistic... | May 11, 2023
May 8, 2023
– Phase 1 data provide rationale for sebetralstat as short-term prophylaxis for medical and dental procedures - – Patient survey data demonstrate treatment burden associated with... | May 8, 2023
May 8, 2023
Top-line data from CHAPTER-1, a proof-of-concept Phase 2 study of PHVS416 for the prophylactic treatment of HAE, anticipated by YE2023Executing from a strong financial position with cash and cash... | May 8, 2023
May 6, 2023
ZUG, Switzerland, May 06, 2023 -- Pharvaris , a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema attacks, today announced... | May 6, 2023
May 6, 2023
06.05.2023 - ZUG, Switzerland, May 06, 2023 (GLOBE NEWSWIRE) - Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced two oral ... Seite 1
April 28, 2023
Astria Therapeutics, Inc. , a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and... | April 28, 2023